Ask AI
ProCE Banner Activity

CAMMA 1: Updated Safety, Efficacy, and Biomarker Analyses From Phase I Study of Cevostamab + Pomalidomide + Dexamethasone in BCMA1-Naive RRMM

Conference Coverage
Slideset

In this phase Ib study, the FcRH5 x CD3 bispecific antibody cevostamab given in combination with pomalidomide and dexamethasone was associated with high response rates and durable remissions in patients with BCMA-naive RRMM; AEs were reversible and often managed with dose delays.

Released: December 09, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Appraise how new trial findings might advance the treatment of patients with malignant or nonmalignant hematologic disorders in the future

  • Support informed shared decision-making for patients with malignant and nonmalignant hematologic disorders through accessible discussion of the potential clinical implications of recently presented data